The recent study by Turner et al. (2023) on hormone receptor-positive advanced breast cancer showcased significant improvements in progression-free and overall survival with capivasertib, cementing its status as a potent therapeutic agent [6]. The gene discussed is NR4A1; the disease is breast cancer.